How Many Percutaneous Puncture Surgical Robots Are There in China?

As of August 25, 2026, the MedRobot database had recorded 23 registration certificates related to percutaneous puncture surgical robots, involving 15 registrants. Of these, 21 were for domestic products and two for imported products.

By number of registration certificates, puncture robots rank second only to orthopedic robots, which have 79 certificates, making them the second-largest surgical robotics segment in China by number of registered products.

MedRobot reviewed the company distribution behind these 23 certificates, their clinical applications, the evolution of product functions, and the gap between the number of registered products and publicly available sales data.

Note: In this article, “percutaneous puncture” refers to procedures in which physicians insert needles or other instruments through the skin into target tissues or organs for biopsy, ablation, drainage and other diagnostic or therapeutic purposes. These procedures are typically performed under imaging guidance such as CT or ultrasound. Puncture surgical robots are used to assist with needle-path planning, puncture-site positioning and needle-direction control. Some systems can also perform automated needle insertion to improve procedural accuracy and stability.

True Health Holds Seven Certificates, Tuodao Medical Two and Weide Jingzhun Two; 15 Companies Cover Applications From Lung Puncture to Prostate Biopsy

Among the 23 registration certificates, True Health accounts for seven, with a product portfolio extending from navigation for lung and abdominal solid-organ puncture procedures to microwave ablation of solid liver tumors.

Tuodao Medical holds two certificates. Its NP100 targets lung and abdominal puncture procedures, while the PB100 focuses on transperineal prostate puncture biopsy.

Weide Jingzhun also holds two certificates. The company also has an innovative ultrasound-guided percutaneous renal intervention product currently undergoing registration, giving it a relatively diversified presence in the segment.

The remaining 12 companies each hold one registration certificate, creating a market structure characterized by concentration at the top and a fragmented long tail.

In terms of applications, most products focus on CT-guided navigation and positioning for percutaneous puncture of the lungs and abdominal solid organs. Core clinical scenarios include lung nodule biopsy, liver lesion puncture, tumor biopsy and needle-tract establishment before ablation.

These systems can be used across multiple departments, including interventional radiology, respiratory medicine, thoracic surgery and hepatobiliary surgery.

For prostate puncture, only two registered products were identified: Mona Lisa, involving MicroPort’s interventional navigation business in cooperation with Biobot Surgical, and Tuodao Medical’s PB100.

Both are used for transperineal prostate biopsy under transrectal ultrasound guidance. Their imaging methods and clinical workflows differ significantly from CT-guided lung puncture procedures.

Approvals Concentrated Over Four Years, With 2024 Marking the Peak

The rapid increase in registered puncture surgical robots in China has been concentrated over the past four years.

In 2022, only one product was approved — True Health’s TH-S1, when the segment was still at an early stage of development.

In 2024, approvals reached a peak, with eight new registration certificates issued in a single year. Companies including Ruichu, Ariemedi, Curaway Medical, Weide Jingzhun and Yida Jixing entered the market during this period, marking a significant expansion of the segment.

In 2025, another seven certificates were added, with companies including United Imaging Surgical, Aimite Zhineng, ZOYE Medical and HANGLOK obtaining registrations. The number of market participants continued to expand.

By August 25, 2026, another three registration certificates had been added.

[Insert Image 3 here — annual number of puncture surgical robot registration certificates]

Product Evolution: From Navigation Alone to Needle Insertion Control and Integrated Diagnosis and Treatment

Early puncture surgical robot registrations primarily focused on navigation and positioning.

Their main functions were surgical-path planning and needle-trajectory positioning, with the robot serving primarily as an auxiliary positioning tool and playing a relatively limited role in the actual procedure.

More recently approved products have expanded these functional boundaries, with robots taking a more active role during procedures.

Two newer products — United Imaging Surgical’s uInterv C550 series and MicroIGT-RoboC — explicitly include both “navigation and positioning” and “needle insertion control” within their registered scope.

This extends the role of puncture robots from path-planning assistance into intraoperative needle-control functions.

Another important direction is the integration of navigation with therapeutic equipment, moving beyond a single guidance function.

True Health’s TH-X MW and TH-X HMW, for example, are registered as navigation and positioning microwave ablation systems. Based on CT images, the systems can be used to formulate puncture plans, guide microwave ablation needles during percutaneous insertion, and support microwave ablation treatment of solid liver tumors in adults.

Commercialization: After 23 Registration Certificates, the Market Remains at an Early Stage

Registration data show that China’s puncture surgical robotics segment is continuing to expand, but commercialization remains at an early stage.

Based on MedRobot’s analysis of publicly disclosed procurement results from public hospitals, one puncture robot was publicly recorded as sold in 2024, 12 in 2025, and four in the first half of 2026.

This dataset does not fully cover research-related installations, purchases by private hospitals or orders that were not publicly tendered, and therefore should not be regarded as representing total industry sales.

The gap can be understood from two perspectives.

First, the segment is still at an early stage of development, while changes in the medical equipment procurement environment in recent years mean that market adoption will take time.

Percutaneous puncture robots are still a relatively new category of medical equipment. Many products have only completed registration in recent years, while clinical awareness, application experience and procurement demand are still developing.

At the same time, hospitals have placed greater emphasis in recent years on return on investment, clinical value and the efficiency of capital use, making purchasing decisions for new equipment more cautious.

Under these conditions, growth in the number of approved products does not necessarily translate directly into rapid growth in procurement.

Second, the clinical use of new equipment requires value validation and workflow adaptation.

Conventional CT- and ultrasound-guided puncture techniques are already relatively mature.

For puncture robots to achieve broader adoption, additional clinical evidence will be needed in areas such as puncture accuracy, procedural efficiency, radiation protection and physician learning curves.

Clinical requirements and workflows also differ across organs and imaging modalities. Products therefore need to fit hospitals’ existing equipment layouts, physicians’ operating habits and departmental workflows.

These factors need to be refined gradually through real-world use and cannot be resolved immediately after regulatory approval.

Overall, as clinical evidence accumulates, products become better integrated with existing workflows, and hospitals develop a clearer understanding of their practical value, the foundation for further development of the percutaneous puncture surgical robotics market is likely to strengthen.

Data Note

Registration certificate data in this article are sourced from MedRobot’s China Approved Surgical Robot Registration Certificate Database, with data current as of August 25, 2026.

Sales data are based primarily on publicly disclosed procurement results from public hospitals, supplemented by information provided by some companies. Disclosure levels vary between companies, and the figures are intended only to provide an indication of the current stage of market commercialization.

November 1, 2026